Status:
ACTIVE_NOT_RECRUITING
A Study of N-acetylcysteine in Patients With COVID-19 Infection
Lead Sponsor:
Memorial Sloan Kettering Cancer Center
Conditions:
Covid-19
Eligibility:
All Genders
18+ years
Phase:
PHASE2
Brief Summary
The study researchers think that a medication called N-acetylcysteine can help fight the COVID-19 virus by boosting a type of cell in your immune system that attacks infections. By helping your immune...
Eligibility Criteria
Inclusion
- Documented COVID-19 infection (either performed on site or documented external report)
- Age ≥ 18
- Arm A:
- Admission to an intensive care unit at MSK (M-11) and/or receiving mechanical ventilation
- Absolute lymphocyte count ≤ 1.0/mm3
- As the ALC of patients with lymphoid malignancies is unreliable, they may be enrolled at the discretion of the treating physician after review of their blood work.
- Arm B:
- Arm B:Requiring 2L or more of supplemental oxygen by nasal cannula or higher to maintain SpO2 of 95%
Exclusion
- Arm B:
- requiring mechanical ventilation or admission to an intensive care unit at MSK (M11)
Key Trial Info
Start Date :
May 1 2020
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
May 1 2026
Estimated Enrollment :
48 Patients enrolled
Trial Details
Trial ID
NCT04374461
Start Date
May 1 2020
End Date
May 1 2026
Last Update
December 15 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Memorial Sloan Kettering Cancer Center
New York, New York, United States, 10065